Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy

Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs. Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies. In this review, we summarized the current understandi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bin-Bin Li, Bo Wang, Cheng-Ming Zhu, Di Tang, Jun Pang, Jing Zhao, Chun-Hui Sun, Miao-Juan Qiu, Zhi-Rong Qian
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2019
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c65a4a41082d4663a0cc81b8d4f5703e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c65a4a41082d4663a0cc81b8d4f5703e
record_format	dspace
spelling	oai:doaj.org-article:c65a4a41082d4663a0cc81b8d4f5703e2021-12-02T11:52:55ZCyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy2095-882X10.1016/j.cdtm.2019.08.006https://doaj.org/article/c65a4a41082d4663a0cc81b8d4f5703e2019-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X19300714https://doaj.org/toc/2095-882XCurrent cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs. Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies. In this review, we summarized the current understanding with THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which demonstrated promising anti-tumor activity against different cancer types. By introducing the anti-tumor behaviors and the potential targets for different cancers, this review aims to provide more effective approaches to CDK7 inhibitor-based therapeutic agents and deeper insight into the diverse tumor proliferation mechanisms. Keywords: THZ1, Cyclin-dependent kinase 7, Cancer therapy, Transcription, Super-enhancerBin-Bin LiBo WangCheng-Ming ZhuDi TangJun PangJing ZhaoChun-Hui SunMiao-Juan QiuZhi-Rong QianKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 5, Iss 3, Pp 155-169 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Bin-Bin Li Bo Wang Cheng-Ming Zhu Di Tang Jun Pang Jing Zhao Chun-Hui Sun Miao-Juan Qiu Zhi-Rong Qian Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
description	Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs. Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies. In this review, we summarized the current understanding with THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which demonstrated promising anti-tumor activity against different cancer types. By introducing the anti-tumor behaviors and the potential targets for different cancers, this review aims to provide more effective approaches to CDK7 inhibitor-based therapeutic agents and deeper insight into the diverse tumor proliferation mechanisms. Keywords: THZ1, Cyclin-dependent kinase 7, Cancer therapy, Transcription, Super-enhancer
format	article
author	Bin-Bin Li Bo Wang Cheng-Ming Zhu Di Tang Jun Pang Jing Zhao Chun-Hui Sun Miao-Juan Qiu Zhi-Rong Qian
author_facet	Bin-Bin Li Bo Wang Cheng-Ming Zhu Di Tang Jun Pang Jing Zhao Chun-Hui Sun Miao-Juan Qiu Zhi-Rong Qian
author_sort	Bin-Bin Li
title	Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
title_short	Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
title_full	Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
title_fullStr	Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
title_full_unstemmed	Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
title_sort	cyclin-dependent kinase 7 inhibitor thz1 in cancer therapy
publisher	KeAi Communications Co., Ltd.
publishDate	2019
url	https://doaj.org/article/c65a4a41082d4663a0cc81b8d4f5703e
work_keys_str_mv	AT binbinli cyclindependentkinase7inhibitorthz1incancertherapy AT bowang cyclindependentkinase7inhibitorthz1incancertherapy AT chengmingzhu cyclindependentkinase7inhibitorthz1incancertherapy AT ditang cyclindependentkinase7inhibitorthz1incancertherapy AT junpang cyclindependentkinase7inhibitorthz1incancertherapy AT jingzhao cyclindependentkinase7inhibitorthz1incancertherapy AT chunhuisun cyclindependentkinase7inhibitorthz1incancertherapy AT miaojuanqiu cyclindependentkinase7inhibitorthz1incancertherapy AT zhirongqian cyclindependentkinase7inhibitorthz1incancertherapy
_version_	1718394951640809472

Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy

Ejemplares similares